Winnow Wealth LLC Raises Stock Holdings in Elanco Animal Health Incorporated $ELAN

Winnow Wealth LLC boosted its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 271,064.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 37,963 shares of the company’s stock after purchasing an additional 37,949 shares during the period. Winnow Wealth LLC’s holdings in Elanco Animal Health were worth $873,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ELAN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Elanco Animal Health in the first quarter valued at about $2,065,000. Goldman Sachs Group Inc. boosted its holdings in Elanco Animal Health by 104.5% in the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after purchasing an additional 2,445,872 shares during the last quarter. Empowered Funds LLC boosted its holdings in Elanco Animal Health by 35.2% in the first quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock valued at $166,000 after purchasing an additional 4,121 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Elanco Animal Health by 4.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock valued at $18,830,000 after purchasing an additional 76,408 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in Elanco Animal Health by 2,006.9% in the second quarter. Arrowstreet Capital Limited Partnership now owns 310,383 shares of the company’s stock valued at $4,432,000 after purchasing an additional 295,651 shares during the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Insider Activity at Elanco Animal Health

In related news, CEO Jeffrey N. Simmons purchased 4,971 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The shares were acquired at an average price of $20.09 per share, with a total value of $99,867.39. Following the acquisition, the chief executive officer owned 171,971 shares in the company, valued at approximately $3,454,897.39. This trade represents a 2.98% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Rajeev A. Modi purchased 4,911 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was bought at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the acquisition, the insider owned 160,812 shares in the company, valued at approximately $3,272,524.20. The trade was a 3.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 1.14% of the company’s stock.

Elanco Animal Health Trading Up 0.2%

Shares of NYSE ELAN opened at $23.67 on Tuesday. The company has a market cap of $11.82 billion, a price-to-earnings ratio of -47.34, a price-to-earnings-growth ratio of 1.55 and a beta of 1.69. Elanco Animal Health Incorporated has a 12-month low of $13.15 and a 12-month high of $27.72. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60. The stock’s 50 day simple moving average is $22.86 and its 200 day simple moving average is $23.42.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.06. The business had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The business’s revenue was up 14.9% on a year-over-year basis. During the same quarter last year, the business posted $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Equities research analysts expect that Elanco Animal Health Incorporated will post 1.11 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on ELAN. Citigroup increased their price target on Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, May 7th. KeyCorp increased their target price on Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Weiss Ratings downgraded Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th. JPMorgan Chase & Co. increased their target price on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Finally, Wall Street Zen downgraded Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Elanco Animal Health currently has an average rating of “Moderate Buy” and an average target price of $28.20.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.